Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07587658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

Name: This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization — clinical trial record (NCT07587658)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MISSION

StatusNot Yet Recruiting

PhasePhase 4

SponsorRegeneron Pharmaceuticals

Started2026-06-30

View on ClinicalTrials.gov ↗

Regeneron

148 trials monitored

See 16 trials at risk

COPD

1,057 trials monitored

See 28 trials at risk

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days). The study is looking at another research question: • What side effects may happen from taking the study drug

Trial Details

NCT Number	NCT07587658
Lead Sponsor	Regeneron Pharmaceuticals Collaborators: Sanofi
Conditions	Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	754 participants
Start Date	2026-06-30
Primary Completion	2028-07-30 (estimated)
Study Completion	2028-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-14